You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
The study showed that targeted sequencing was feasible, identified many clinically relevant alterations, and directed effective targeted therapy in several cases.
By comparing pre-treatment and post-relapse samples from vemurafenib-treated melanoma patients, researchers uncovered resistance-related cohesin complex mutations.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.
